LATEST MULTIPLE MYELOMA CONTENT

Holding and Bridging Therapies Are Essential Parts of CAR T Process

Five-Year CAR T Data Reflect Long-Term PFS in Multiple Myeloma

Selinexor-Based Triplet Shines in Patients With PI-Naive Myeloma

CAR T Deepens Myeloma Response Over Time, Could Overcome High Risk

Treating Multiple Myeloma With Earlier CAR T-Cell Therapy

Evaluating the Efficacy in the BOSTON Trial for Multiple Myeloma

Talquetamab Dose Modification Maintains Efficacy in Multiple Myeloma

Talquetamab’s Late Toxicities Characterized by Oral and Skin AEs
CASE-BASED ROUNDTABLES
Advertisement
Advertisement






